Tobramycin

The exact 3 mg/g + 1 mg/g 3.5 g human ointment has transparent NDA 050616 identity and current Georgian, EU/EEA and US human authorisations. The inherited GB row was a suspension mismatch and is corrected to unknown exact-form status. No veterinary authorisation exists, and exact-product target-species evidence is absent or limited to one confounded canine case; the evidence gate caps this axis at 4.0.

One exact-ointment canine MGD/blepharitis case improved during ointment plus systemic doxycycline, warm compresses, lid massage and dermatologic care; it cannot isolate efficacy or generalise across ocular disease. Exact rabbit PK confirms delivery but not canine benefit, and dexamethasone increased tobramycin resistance/MIC in canine S. pseudintermedius isolates.

Correct selection can reduce harm, but dexamethasone can delay epithelial healing, mask or enhance infection, raise IOP and contribute to perforation in thinned cornea; the ointment itself may retard healing. Repeated topical 0.1% dexamethasone produced systemic absorption and cortisol suppression in dogs. Exact repeated-ointment target-animal safety is absent.

The sterile ready tube needs no shaking and longer surface residence may suit selected lid/anterior-surface disease. Ribbon length is imprecise, ointment blurs vision and requires atraumatic restraint, tip hygiene and placement after other drops; examination, IOP decisions and early recheck remain substantial but appropriate clinical work.

The exact 3 mg/g + 1 mg/g 3.5 g human ointment has transparent NDA 050616 identity and current Georgian, EU/EEA and US human authorisations. The inherited GB row was a suspension mismatch and is corrected to unknown exact-form status. No veterinary authorisation exists, and exact-product target-species evidence is absent or limited to one confounded canine case; the evidence gate caps this axis at 4.0.

No exact-ointment feline outcome trial was found. Human-label activity, rabbit PK and one confounded canine case are indirect, while common feline herpesvirus disease can make the steroid inappropriate; pure-tobramycin susceptibility cannot prove benefit of this fixed combination.

Ulcer, delayed-healing, infection, IOP and perforation hazards apply, while latent feline herpesvirus adds a species-specific risk. Exact feline PK and repeated-use safety are absent; aminoglycoside hypersensitivity, contamination and non-susceptible overgrowth remain possible.

A ready tube and longer residence may reduce placements, but ribbon length is difficult to quantify in a small painful eye. Greasy residue, temporary blur, restraint, contamination control, other-drop sequencing and early reassessment limit practicality, especially when FHV or another differential may require changing one component.

The exact 0.3%/0.1% human suspension has transparent FDA NDA 050592 identity and current Georgian, EU/EEA, GB and US human authorisations. The old NDA 050616 mapping belonged to ointment and is corrected here; no veterinary authorisation applies and dog/cat use remains off-label.

Exact TobraDex is documented in canine cataract and lens-emergency protocols, supporting a real narrow veterinary role, but outcomes are inseparable from surgery and multiple concurrent drugs. No clean exact-product canine trial was found, and a 2026 study found dexamethasone increased tobramycin resistance/MIC in canine S. pseudintermedius isolates.

A diagnostic error can cause vision-threatening harm: dexamethasone delays epithelial healing, can enhance collagenase-associated melting, mask infection and raise IOP. Four-times-daily 0.1% ophthalmic dexamethasone produced systemic absorption and cortisol suppression in dogs; BAK exposure, aminoglycoside sensitivity and microbial overgrowth add risk.

The 5 ml dropper gives a direct ocular unit without weight calculation, but this suspension must be shaken before every dose and needs repeated administration, careful restraint, contamination control, examination, IOP decisions and early recheck. A fixed combination is less adaptable when only one component should be changed.

The exact 0.3%/0.1% human suspension has transparent FDA NDA 050592 identity and current Georgian, EU/EEA, GB and US human authorisations. The old NDA 050616 mapping belonged to ointment and is corrected here; no veterinary authorisation applies and dog/cat use remains off-label.

No exact-product feline clinical outcome trial was found. Human exact-ratio data and canine multi-treatment experience provide only an indirect bridge, while common feline inflammatory eye disease may be herpetic and therefore steroid-inappropriate; pure-tobramycin susceptibility cannot prove benefit of the fixed combination.

The serious ulcer, infection, healing and IOP hazards apply, and topical corticosteroids can reactivate latent feline herpesvirus with ulcerative keratitis or sequestrum. Exact-product feline safety and systemic-absorption data are absent, so an intact stain today does not remove the need for viral history, lesion assessment and early recheck.

The dropper is directly measurable, but shaking, repeated atraumatic feline restraint, contamination control, examination and early recheck are material burdens. The fixed combination is particularly inflexible when herpesvirus or another differential makes dexamethasone inappropriate while antibacterial treatment is still being reconsidered.

The exact 3 mg/g 3.5 g human ointment has a current transparent FDA label and current Georgian, EU/EEA and US human authorisations. Veterinary literature supports a coherent tobramycin ocular role, but no dog/cat authorisation applies and exact-form use remains off-label.

Canine keratitis series support tobramycin, often with a first-generation cephalosporin, as an empiric component while culture is pending, and a multi-treatment keratomalacia cohort had favourable outcomes. No trial establishes exact Tobrex ointment monotherapy, resistance varies, and concentration/MIC evidence from solutions cannot establish ointment exposure.

Topical exposure limits systemic burden and the exact label reports mainly local hypersensitivity/toxicity, but it explicitly warns that ophthalmic ointments may retard corneal wound healing. Prolonged surface residence, chlorobutanol, contamination, overgrowth and delayed escalation in a deep or melting ulcer are meaningful form-specific risks; systemic toxicity is not assumed from routine short ocular use.

The ready tube needs no reconstitution and longer residence can reduce placement frequency in selected superficial disease. Ribbon length is less precise than one drop, ointment temporarily blurs vision, tip contamination and painful-eye restraint matter, and the wound-healing warning makes it less convenient for frequent use or rapidly progressive ulceration.

The exact 3 mg/g 3.5 g human ointment has a current transparent FDA label and current Georgian, EU/EEA and US human authorisations. Veterinary literature supports a coherent tobramycin ocular role, but no dog/cat authorisation applies and exact-form use remains off-label.

A feline bacterial-keratitis series found 86% aggregate in vitro tobramycin susceptibility, supporting an organism-directed option. Exact ointment outcome trials are absent, common feline disease is often viral or non-bacterial, and activity gaps remain; neither solution data nor human ointment efficacy can be treated as feline clinical cure.

Topical exposure limits systemic burden and the exact label reports mainly local hypersensitivity/toxicity, but it explicitly warns that ophthalmic ointments may retard corneal wound healing. Prolonged surface residence, chlorobutanol, contamination, overgrowth and delayed escalation in a deep or melting ulcer are meaningful form-specific risks; systemic toxicity is not assumed from routine short ocular use.

The ready tube and longer residence can be useful when a feline patient tolerates fewer placements, but ribbon length is difficult to quantify in a small painful eye. Temporary visual blur, greasy residue, tip contamination, restraint and the wound-healing warning reduce exact-form practicality, especially when the primary disease also requires other drops.

The exact 0.3% human solution has a transparent FDA product record and current Georgian, EU/EEA and US human authorisations. Veterinary literature supports a coherent ocular role, but no dog/cat authorisation applies and all assessed use remains off-label.

Canine keratitis series support tobramycin, usually with a first-generation cephalosporin, as a useful empiric component while culture is pending, and a multi-treatment keratomalacia cohort had favourable globe/vision outcomes. Exact Tobrex monotherapy trials are lacking, susceptibility varies, and commercial 0.3% may not reach inhibitory exposure for some Pseudomonas isolates.

Topical use limits systemic exposure and tobramycin is comparatively tolerable among aminoglycosides, but the exact solution contains 0.01% benzalkonium chloride and frequent treatment on damaged cornea can add epithelial toxicity. Local hypersensitivity, contamination, resistant or fungal overgrowth and treatment delay in rapidly melting disease are clinically important; systemic aminoglycoside toxicity is not assumed from routine short ophthalmic use.

The ready 5 ml solution needs no shaking or reconstitution and one-drop delivery is straightforward. Several daily doses or intensive specialist schedules, painful-eye restraint, tip hygiene, culture and short rechecks add real clinical workload; the bottle cannot be treated as a substitute for fortified therapy when MIC and ulcer severity demand another concentration.

The exact 0.3% human solution has a transparent FDA product record and current Georgian, EU/EEA and US human authorisations. Veterinary literature supports a coherent ocular role, but no dog/cat authorisation applies and all assessed use remains off-label.

A feline bacterial-keratitis series found 86% aggregate in-vitro susceptibility to tobramycin, supporting a reasonable option when a bacterial target is likely. Direct exact-product outcome trials are absent, common feline ocular disease is often viral or non-bacterial, and activity against streptococci/anaerobes is limited; susceptibility is not clinical cure.

Topical use limits systemic exposure and tobramycin is comparatively tolerable among aminoglycosides, but the exact solution contains 0.01% benzalkonium chloride and frequent treatment on damaged cornea can add epithelial toxicity. Local hypersensitivity, contamination, resistant or fungal overgrowth and treatment delay in rapidly melting disease are clinically important; systemic aminoglycoside toxicity is not assumed from routine short ophthalmic use.

The ready solution needs no shaking, reconstitution or systemic dose calculation, but accurate delivery can be difficult in a painful or poorly tolerant cat. Repeated restraint, strict tip hygiene, several daily administrations, culture and short rechecks are material constraints, especially when bacterial infection is secondary to a feline-specific primary disease.